References
  1. Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020; 382:1787-1799.
  2. RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2020;396:1345-1352.
  3. The RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med 2020;383:2030-2040
  4. Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA 2020;323:2493-2502.
  5. Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate COVID-19. N Engl J Med 2020;383:2041-2052.
  6. WHO Solidarity trial consortium. Repurposed antiviral drugs for COVID-19 –interim WHO Solidarity trial results. N Engl J Med 2020 December 2. [Epub ahead of print]
  7. Beigel JH, Tomashek KM, Dodd LE. et al. Remdesivir for the treatment of COVID-19—final report. N Engl J Med 2020; 383: 1813-1826.
  8. Cai Q, Yanga M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering 2020;6:1192-1198.
  9. Chen C, Zhang Y, Huang J, et al. Favipiravir versus arbidol for COVID-19: A randomized clinical trial. BMJ 2020 April 15. [Epub ahead of print]
  10. Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. Avifavir for treatment of patients with moderate COVID-19: Interim results of a phase II/III multicenter randomized clinical trial. Clin Infect Dis 2020 August 9. [Epub ahead of print]
  11. Weiss A, Jellingsø M, Sommera MOA. Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: A systematic review and meta-analysis. EBioMedicine 2020; 58:102916.
  12. RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19 - preliminary report. N Engl J Med 2020 July 17; 58:102916.
Table 1 . Univariate and multivariate analysis among symptomatic COVID-19 patients and risk factors associated with composite poor outcome (defined as at least one of the outcomes: requiring high-flow oxygen therapy, being intubated with mechanical ventilation, admission to ICU, or death).